{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-010226","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.278465+00:00","generated_at":"2026-05-14T21:33:45.651659+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tonix shareholders approve reverse stock split authorization and 2026 equity plan at annual meeting","bullets":["Reverse stock split authorized up to 1:250 ratio; 4,400,765 votes for, 2,826,586 against.","2026 Stock Incentive Plan approved; 2,019,646 for, 1,624,412 against, 3,504,257 broker non-votes.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2026; 6,910,516 votes for.","Nine directors re-elected including CEO Seth Lederman; all nominees received >84% of votes cast.","Shareholder turnout 54.22% (7,267,759 shares of 13.4M outstanding) on record date March 19, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-010226","json":"https://secwatch.observer/filing/0001999371-26-010226.json","markdown":"https://secwatch.observer/filing/0001999371-26-010226.md","text":"https://secwatch.observer/filing/0001999371-26-010226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/0001999371-26-010226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/tnxp-8k_050726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:33:45.651659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dcd086c9d2b839540c93e3ceaf603a19ddb5328","claim":"Tonix Pharmaceuticals Holding Corp. shareholders approved Approval of 2026 Stock Incentive Plan at the 2026-05-07 meeting.","evidence_excerpt":"The Company’s shareholders approved a proposal to approve the Plan, as set forth below: Votes Non-Votes 2,019,646 1,624,412 119,444 3,504,257","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/0001999371-26-010226-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-07"}],"fact_type":"shareholder_vote"},{"claim_id":"8790533f4c4cd82d5b01e23c18fb536efce98222","claim":"Tonix Pharmaceuticals Holding Corp. shareholders approved Authorization of reverse stock split at the 2026-05-07 meeting.","evidence_excerpt":"The Company’s shareholders approved a proposal to authorize the Company’s Board of Directors (the “Board”), in its discretion at any time within two years of May 7, 2026, to effect on or more reverse stock splits of then-outstanding shares of the Company’s common stock, at an aggregate ratio of not less than one-for-two (1:2) and not greater than one-for-two-hundred-and-fifty (1:250), with the exact ratio, number and timing of the reverse stock splits to be determined by the Board and included in a public announcement, as set forth below: Votes Non-Votes 4,400,765 2,826,586 40,408 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/0001999371-26-010226-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-07"}],"fact_type":"shareholder_vote"},{"claim_id":"8fb9f5ab564ab78c0e43377674ea0af2e266f8c1","claim":"Tonix Pharmaceuticals Holding Corp. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-05-07 meeting.","evidence_excerpt":"The Company’s shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth below: Votes Non-Votes 6,910,516 189,838 167,405 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/0001999371-26-010226-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-07"}],"fact_type":"shareholder_vote"},{"claim_id":"9860f584b8cc252c31168d32cc29a00d8e883184","claim":"Tonix Pharmaceuticals Holding Corp. shareholders approved Election of nine directors at the 2026-05-07 meeting.","evidence_excerpt":"The Company’s shareholders elected nine individuals to the Board of Directors as set forth below: Name Votes For Votes Withheld Broker Non-Votes Seth Lederman 3,188,336 575,166 3,504,257 Richard Bagger 3,278,146 485,356 3,504,257 Margaret Smith Bell 3,274,181 489,321 3,504,257 David Grange 3,275,761 487,741 3,504,257 James Hunter 3,291,721 471,781 3,504,257 Adeoye Olukotun 3,277,352 486,150 3,504,257 R. Newcomb Stillwell 3,279,883 483,619 3,504,257 Carolyn Taylor 3,280,942 482,560 3,504,257 James Treco 3,279,367 484,135 3,504,257","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/0001999371-26-010226-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}